Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

A Pilot Randomized Trial Assessing the Effect of a Psychoeducational Intervention on Psychoneuroimmunological Parameters Among Patients With Nonmetastatic Breast Cancer.

Stanzer S, Andritsch E, Zloklikovits S, Ladinek V, Farkas C, Augustin T, Obermayer-Pietsch B, Samonigg H, Bauernhofer T.

Psychosom Med. 2019 Feb/Mar;81(2):165-175. doi: 10.1097/PSY.0000000000000656.

PMID:
30489436
2.

Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.

Eisterer W, Piringer G, DE Vries A, Öfner D, Greil R, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group.

Anticancer Res. 2017 May;37(5):2683-2691.

PMID:
28476845
3.

Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.

Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H, Beyer J, Winder T, Hermanns T, Fankhauser CD, Gerger A, Stotz M.

PLoS One. 2017 Apr 21;12(4):e0176283. doi: 10.1371/journal.pone.0176283. eCollection 2017.

4.

Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.

Suppan C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, Eberhard K, Samonigg H, Loibner H, Dandachi N, Balic M.

BMC Cancer. 2015 Dec 29;15:1027. doi: 10.1186/s12885-015-2005-3.

5.

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.

Kandioler D, Mittlböck M, Kappel S, Puhalla H, Herbst F, Langner C, Wolf B, Tschmelitsch J, Schippinger W, Steger G, Hofbauer F, Samonigg H, Gnant M, Teleky B, Kührer I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG).

EBioMedicine. 2015 Jun 8;2(8):825-30. doi: 10.1016/j.ebiom.2015.06.003. eCollection 2015 Aug.

6.

A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.

Eisner F, Pichler M, Goletz S, Stoeger H, Samonigg H.

J Clin Pathol. 2015 Dec;68(12):1044-6. doi: 10.1136/jclinpath-2015-202996. Epub 2015 Sep 18. No abstract available.

7.

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M.

Br J Cancer. 2015 Apr 14;112(8):1405-10. doi: 10.1038/bjc.2015.98. Epub 2015 Mar 24.

8.

Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.

Reitz D, Gerger A, Seidel J, Kornprat P, Samonigg H, Stotz M, Szkandera J, Pichler M.

J Clin Pathol. 2015 Jun;68(6):427-33. doi: 10.1136/jclinpath-2014-202451. Epub 2015 Mar 10. Erratum in: J Clin Pathol. 2015 Jul;68(7):e2.

PMID:
25759406
9.

LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.

Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberl-Moser R, Samonigg H, Asslaber M, Lax S, Leitner G, Renner W, Lenz HJ, Berghold A, Gerger A.

Pharmacogenomics J. 2015 Oct;15(5):391-6. doi: 10.1038/tpj.2015.2. Epub 2015 Feb 10.

10.

The derived neutrophil/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients.

Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Friesenbichler J, Stojakovic T, Leithner A, Pichler M.

Am J Surg. 2015 Jul;210(1):111-6. doi: 10.1016/j.amjsurg.2014.10.021. Epub 2014 Dec 18.

PMID:
25586599
11.

The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer.

Stotz M, Szkandera J, Stojakovic T, Seidel J, Samonigg H, Kornprat P, Schaberl-Moser R, Seggewies F, Hoefler G, Gerger A, Pichler M.

Clin Chem Lab Med. 2015 Feb;53(3):499-506. doi: 10.1515/cclm-2014-0447.

PMID:
25389993
12.

Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients.

Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Ploner F, Stojakovic T, Gary T, Leithner A, Pichler M.

Clin Chem Lab Med. 2015 Feb;53(3):493-7. doi: 10.1515/cclm-2014-0486.

PMID:
25324451
13.

MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients.

Ress AL, Stiegelbauer V, Winter E, Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A, Bauernhofer T, Ling H, Samonigg H, Gerger A, Hoefler G, Pichler M.

Mol Carcinog. 2015 Nov;54(11):1442-50. doi: 10.1002/mc.22218. Epub 2014 Sep 25.

PMID:
25256312
14.

Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients.

Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Ploner F, Stojakovic T, Leithner A, Pichler M.

PLoS One. 2014 Sep 10;9(9):e107297. doi: 10.1371/journal.pone.0107297. eCollection 2014.

15.

Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients.

Stotz M, Szkandera J, Seidel J, Stojakovic T, Samonigg H, Reitz D, Gary T, Kornprat P, Schaberl-Moser R, Hoefler G, Gerger A, Pichler M.

PLoS One. 2014 Aug 18;9(8):e104730. doi: 10.1371/journal.pone.0104730. eCollection 2014.

16.

The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients.

Szkandera J, Pichler M, Absenger G, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Kornprat P, Stojakovic T, Avian A, Gerger A.

Am J Surg. 2014 Aug;208(2):210-4. doi: 10.1016/j.amjsurg.2013.10.030. Epub 2014 Jan 24.

PMID:
24581872
17.

A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.

Szkandera J, Pichler M, Absenger G, Stotz M, Weissmueller M, Samonigg H, Asslaber M, Lax S, Leitner G, Winder T, Renner W, Gerger A.

Clin Cancer Res. 2014 Mar 15;20(6):1687-97. doi: 10.1158/1078-0432.CCR-13-1517. Epub 2014 Jan 27.

18.

An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.

Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, Samonigg H, Eucker J, Possinger K, Wischnewsky MB.

Ann Oncol. 2014 Mar;25(3):633-8. doi: 10.1093/annonc/mdt539. Epub 2013 Dec 23.

19.

The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.

Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A.

Br J Cancer. 2014 Jan 21;110(2):435-40. doi: 10.1038/bjc.2013.785. Epub 2013 Dec 19.

20.

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, Casali PG, Sessa C, Van Cutsem E, de Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart M.

Ann Oncol. 2014 Jan;25(1):9-15. doi: 10.1093/annonc/mdt522. Epub 2013 Dec 13. Erratum in: Ann Oncol. 2014 Apr;25(4):916.

21.

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N.

Mod Pathol. 2014 Jun;27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.

22.

External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.

Szkandera J, Stotz M, Eisner F, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M.

PLoS One. 2013 Nov 4;8(11):e78225. doi: 10.1371/journal.pone.0078225. eCollection 2013.

23.

Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.

Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Lackner C, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M.

Br J Cancer. 2014 Jan 7;110(1):183-8. doi: 10.1038/bjc.2013.701. Epub 2013 Nov 7.

24.

Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer.

Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress AL, Schaberl-Moser R, Loibner H, Samonigg H, Gerger A.

Anticancer Res. 2013 Oct;33(10):4591-4.

PMID:
24123035
25.

The elevated pre-operative plasma fibrinogen level is an independent negative prognostic factor for cancer-specific, disease-free and overall survival in soft-tissue sarcoma patients.

Szkandera J, Pichler M, Liegl-Atzwanger B, Absenger G, Stotz M, Ploner F, Stojakovic T, Samonigg H, Eberhard K, Leithner A, Gerger A.

J Surg Oncol. 2014 Feb;109(2):139-44. doi: 10.1002/jso.23458.

PMID:
24122271
26.

miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.

Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, Lax S, Samonigg H, Hoefler G.

J Clin Pathol. 2014 Mar;67(3):198-203. doi: 10.1136/jclinpath-2013-201904. Epub 2013 Oct 4.

PMID:
24098024
27.

Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients.

Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, Maurer-Ertl W, Stojakovic T, Ploner F, Leithner A, Pichler M.

Br J Cancer. 2013 Oct 29;109(9):2316-22. doi: 10.1038/bjc.2013.595. Epub 2013 Oct 1.

28.

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R.

Br J Cancer. 2013 Aug 6;109(3):589-96. doi: 10.1038/bjc.2013.367. Epub 2013 Jul 18.

29.

A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients.

Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A.

Br J Cancer. 2013 Jul 23;109(2):395-400. doi: 10.1038/bjc.2013.346. Epub 2013 Jul 2.

30.

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M.

Br J Cancer. 2013 Jul 23;109(2):416-21. doi: 10.1038/bjc.2013.332. Epub 2013 Jun 25. Erratum in: Br J Cancer. 2013 Oct 1;109(7):2026. Zoughbi, W [corrected to AlZoughbi, W].

31.

Association of common gene variants in vitamin D modulating genes and colon cancer recurrence.

Szkandera J, Absenger G, Pichler M, Stotz M, Langsenlehner T, Samonigg H, Renner W, Gerger A.

J Cancer Res Clin Oncol. 2013 Sep;139(9):1457-64. doi: 10.1007/s00432-013-1461-x. Epub 2013 Jun 23.

PMID:
23793229
32.

The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.

Hofmann G, Balic M, Dandachi N, Resel M, Schippinger W, Regitnig P, Samonigg H, Bauernhofer T.

Clin Biochem. 2013 Oct;46(15):1585-9. doi: 10.1016/j.clinbiochem.2013.06.010. Epub 2013 Jun 18.

PMID:
23792261
33.

Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.

Eisner F, Schaberl-Moser R, Gerger A, Samonigg H, Pichler M.

Onkologie. 2013;36(6):368-70. doi: 10.1159/000351252. Epub 2013 May 13.

PMID:
23774152
34.

Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.

Stotz M, Eisner F, Szkandera J, Absenger G, Kornprat P, Lackner C, Samonigg H, Gerger A, Pichler M.

J Clin Pathol. 2013 Sep;66(9):753-7. doi: 10.1136/jclinpath-2012-201394. Epub 2013 Jun 8.

PMID:
23750038
35.

A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer.

Absenger G, Szkandera J, Stotz M, Pichler M, Winder T, Langsenlehner T, Langsenlehner U, Samonigg H, Renner W, Gerger A.

Mol Carcinog. 2013 Nov;52 Suppl 1:E96-102. doi: 10.1002/mc.22028. Epub 2013 Apr 26.

PMID:
23625573
36.

Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma.

Aigelsreiter A, Ress AL, Bettermann K, Schauer S, Koller K, Eisner F, Kiesslich T, Stojakovic T, Samonigg H, Kornprat P, Lackner C, Haybaeck J, Pichler M.

Br J Cancer. 2013 May 14;108(9):1830-7. doi: 10.1038/bjc.2013.165. Epub 2013 Apr 16.

37.

The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.

Absenger G, Benhaim L, Szkandera J, Zhang W, Yang D, Labonte MJ, Pichler M, Stotz M, Samonigg H, Renner W, Gerger A, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):130-4. doi: 10.1038/tpj.2013.15. Epub 2013 Apr 9.

PMID:
23567490
38.

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, Benezeder T, Auer M, Pischler C, Mannweiler S, Pichler M, Eisner F, Haeusler M, Riethdorf S, Pantel K, Samonigg H, Hoefler G, Augustin H, Geigl JB, Speicher MR.

Genome Med. 2013 Apr 5;5(4):30. doi: 10.1186/gm434. eCollection 2013.

39.

Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients.

Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, Glehr M, Zacherl M, Stojakovic T, Gerger A, Leithner A.

Br J Cancer. 2013 Apr 30;108(8):1677-83. doi: 10.1038/bjc.2013.135. Epub 2013 Apr 4.

40.

A common gene variant in PLS3 predicts colon cancer recurrence in women.

Szkandera J, Winder T, Stotz M, Weissmueller M, Langsenlehner T, Pichler M, Samonigg H, Renner W, Gerger A, Absenger G.

Tumour Biol. 2013 Aug;34(4):2183-8. doi: 10.1007/s13277-013-0754-7. Epub 2013 Apr 3.

PMID:
23549633
41.

Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.

Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M; ABCSG.

Br J Cancer. 2013 Apr 16;108(7):1408-14. doi: 10.1038/bjc.2013.114. Epub 2013 Mar 19.

42.

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.

Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Cancer Res. 2013 May 15;73(10):2965-75. doi: 10.1158/0008-5472.CAN-12-4140. Epub 2013 Mar 7.

43.

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Höfler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Int J Cancer. 2013 Jul 15;133(2):346-56. doi: 10.1002/ijc.28030. Epub 2013 Feb 13.

44.

IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer.

Heitzer E, Sandner-Kiesling A, Schippinger W, Stohscheer I, Osprian I, Bitsche S, Eisner F, Verebes J, Hofmann G, Samonigg H.

Pain Physician. 2012 Nov-Dec;15(6):499-510.

45.

Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival.

Gary T, Belaj K, Steidl K, Pichler M, Eisner F, Stöger H, Hafner F, Froehlich H, Samonigg H, Pilger E, Brodmann M.

Br J Cancer. 2012 Oct 9;107(8):1244-8. doi: 10.1038/bjc.2012.401. Epub 2012 Sep 11.

46.

Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Szkandera J, Absenger G, Dandachi N, Regitnig P, Lax S, Stotz M, Samonigg H, Renner W, Gerger A.

Mol Genet Genomics. 2012 Sep;287(9):755-64. doi: 10.1007/s00438-012-0715-7. Epub 2012 Aug 18.

PMID:
22903472
47.

The ethics of space, design and color in an oncology ward.

Andritsch E, Stöger H, Bauernhofer T, Andritsch H, Kasparek AK, Schaberl-Moser R, Ploner F, Samonigg H.

Palliat Support Care. 2013 Jun;11(3):215-21. doi: 10.1017/S1478951512000077. Epub 2012 Aug 10.

PMID:
22883931
48.

The functional polymorphism of erythropoietin gene rs1617640 G>T is not associated with susceptibility and clinical outcome of early-stage breast cancer.

Szkandera J, Absenger G, Stotz M, Weissmueller M, Winder T, Langsenlehner T, Samonigg H, Renner W, Schippinger W, Gerger A.

Anticancer Res. 2012 Aug;32(8):3473-8.

PMID:
22843933
49.

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.

Pichler M, Winter E, Stotz M, Eberhard K, Samonigg H, Lax S, Hoefler G.

Br J Cancer. 2012 May 22;106(11):1826-32. doi: 10.1038/bjc.2012.175. Epub 2012 May 1.

50.

Sunitinib causes dose-dependent negative functional effects on myocardium and cardiomyocytes.

Rainer PP, Doleschal B, Kirk JA, Sivakumaran V, Saad Z, Groschner K, Maechler H, Hoefler G, Bauernhofer T, Samonigg H, Hutterer G, Kass DA, Pieske B, von Lewinski D, Pichler M.

BJU Int. 2012 Nov;110(10):1455-62. doi: 10.1111/j.1464-410X.2012.11134.x. Epub 2012 Apr 17.

Supplemental Content

Loading ...
Support Center